NIH Cancels Trial Evaluating Benefit Of Lower Cholesterol Levels
This article was originally published in The Pink Sheet Daily
National Heart, Lung & Blood Institute halts procurement for the study, citing budget constraints.
You may also be interested in...
The National Heart, Lung & Blood Institute plans to start the 5,700-patient clinical study early next year.
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.